These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3480697)

  • 1. The use of CA-50 radioimmunoassay test in diagnosis of urologic malignancy. Tie for second place Jobst award.
    Hershman MJ; Habib NA; Ferro MA; Williamson RC; Wood CB
    Am Surg; 1987 Dec; 53(12):691-4. PubMed ID: 3480697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A clinical study on the tumor associated antigen CA50 in the monitoring of genitourinary malignancies].
    Li CL; Xu BZ; Chen ZZ
    Zhonghua Zhong Liu Za Zhi; 1994 Mar; 16(2):148-51. PubMed ID: 7924868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary tissue factor levels in patients with bladder and prostate cancer.
    Lwaleed BA; Francis JL; Chisholm M
    Eur J Surg Oncol; 2000 Feb; 26(1):44-9. PubMed ID: 10718179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of carcinoembryonic antigen (CEA) in the diagnosis of malignant tumors of the urogenital tract].
    Rost A; Kneppenberg U; Rost P
    Helv Chir Acta; 1976 Jul; 43(3):271-8. PubMed ID: 947865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
    Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
    Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer].
    Tozuka K; Yonese Y; Nakagami Y; Minowa T; Hiraoka Y; Yamada N; Hikima N; Ishii Y; Tannowa K; Fujioka Y
    Gan To Kagaku Ryoho; 1984 May; 11(5):1078-83. PubMed ID: 6721513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preliminary application of carbohydrate antigen CA-50 radioimmunoinhibition test in diagnosing and monitoring cancers].
    Chen ZZ; Fan ZF; Su P
    Zhonghua Zhong Liu Za Zhi; 1987 Nov; 9(6):436-8. PubMed ID: 2838242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of CA-50 radioimmunoassay inhibition test in the differential diagnosis of benign and malignant breast disease.
    Hershman MJ; Habib NA; Kelly SB; Beynon J; Williamson RC; Davies PW; Wood CB
    Eur J Surg Oncol; 1988 Oct; 14(5):413-5. PubMed ID: 3181445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cancer associated antigen test as an index to failure of complete removal of urological cancers.
    Wechsler M; Lo Gerfo P; Feminella J; Lattimer JK
    Trans Am Assoc Genitourin Surg; 1972; 64():85-7. PubMed ID: 4347503
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical experience with the carbohydrate antigen CA-50 in the serum of patients with prostatic carcinoma: a preliminary report.
    Melloni D; Cacciatore M; Carreca I; Cigno A; Laconi A; Pavone-Macaluso M
    J Exp Pathol; 1987; 3(4):369-73. PubMed ID: 2457664
    [No Abstract]   [Full Text] [Related]  

  • 12. Monoclonal antibodies to human prostate and bladder tumor-associated antigens.
    Starling JJ; Sieg SM; Beckett ML; Schellhammer PF; Ladaga LE; Wright GL
    Cancer Res; 1982 Aug; 42(8):3084-9. PubMed ID: 7046915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
    Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
    J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of M43: a novel cancer-associated mucin epitope.
    Goodgame R; Kiefe C; Rose E; Sutton F; Brown J; Alpert E
    Cancer Res; 1993 Jun; 53(12):2803-9. PubMed ID: 7684947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of serum CA 19.9 as a tumour marker in patients with carcinoma of the bladder and prostate.
    Abel PD; Cornell C; Buamah PK; Williams G
    Br J Urol; 1987 May; 59(5):427-9. PubMed ID: 3474046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
    Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
    Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On reference values for tumor markers in prostatic carcinoma.
    Lewenhaupt A; Ekman P; Eneroth P; Kallner A
    Scand J Urol Nephrol Suppl; 1988; 110():119-23. PubMed ID: 3263693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The significance of prostatic serum acid phosphatase as a tumor marker in prostatic cancer].
    Hamami G
    Hinyokika Kiyo; 1983 Oct; 29(10):1231-45. PubMed ID: 6085711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bladder tumor antigen test versus urinary cytology in patients with bladder tumors].
    Gregersen B; Mommsen S; Svanholm H
    Ugeskr Laeger; 1999 Apr; 161(14):2071-3. PubMed ID: 10354792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.